Precigen's reliance on non-recurring milestone payments to drive revenue growth, as evidenced by the $23.3M reported in 2026Q1, obscures a fundamental inability to achieve sustainable operational profitability. The company's aggressive R&D spending, which freq...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.05+514.3% vs -$0.01 | $55M+96.5% vs $28M |
Q2 2026 May 13, 2026 | -$0.02+33.3% vs -$0.03 | $23M+11.8% vs $21M |
Q2 2026 Mar 25, 2026 | -$0.07+33.6% vs -$0.10 | $5M-45.6% vs $8M |
Q4 2025 Nov 13, 2025 | -$1.06-1225.0% vs -$0.08 | $3M+484.4% vs $500,000 |
Precigen, Inc. (NASDAQ: PGEN - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $8.04 and last traded at $7.89, with a volume of 5323560 shares. The stock had previously closed at $7.70. Analyst Upgrades and Downgrades PGEN has been the subject of a
Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®.
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation. Profitability This table compares Celldex Therapeutics and Precigen's
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
Benchmark PGEN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Precigen, Inc. (PGEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.44 | $2.65B | -5.28 | 146.73% | -2588.21% | -843.57% | — | |
| $2.43 | $283.24M | -2.11 | -51.24% | -1941.09% | -65.08% | — | |
| $17.64 | $1.56B | -5.36 | 627.84% | -87.6% | -372.94% | — | |
| $8.40 | $349.8M | -2470.59 | 10.37% | 69.76% | — | — | |
| $0.95 | $1.86M | -0.08 | -13.43% | -490.33% | -1035.26% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — |
Precigen, Inc. (PGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Precigen, Inc. (PGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 24, 2026·SEC
May 13, 2026·SEC
Get notified when PGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Precigen, Inc. (PGEN) stock FAQ — growth, dividends, profitability & financials explained
Precigen, Inc. (PGEN) reported $85.7M in revenue for fiscal year 2025. This represents a 970% increase from $8.0M in 2011.
Precigen, Inc. (PGEN) grew revenue by 146.7% over the past year. This is strong growth.
Precigen, Inc. (PGEN) reported a net loss of $157.7M for fiscal year 2025.
Precigen, Inc. (PGEN) has a return on equity (ROE) of -843.6%. Negative ROE indicates the company is unprofitable.
Precigen, Inc. (PGEN) had negative free cash flow of $159.9M in fiscal year 2025, likely due to heavy capital investments.
